Platform Advantage Lodo leverages metagenomics, AI/ML and synthetic biology to mine environmentally derived natural products, enabling rapid discovery for undruggable targets. This platform is attractive to pharma seeking diversified libraries and accelerated discovery partnerships.

Oncology Focus An oncology focused internal pipeline presents opportunities for co development or licensing with cancer-focused partners. The asset base may complement proteasome inhibitor programs and broader oncology strategies.

Strategic Partnerships Past collaborations with Genentech and other partners demonstrate credible capability to deliver joint development programs. The Zymergen acquisition could offer expanded resources and scale for future collaborations.

Proteasome Assets Exclusive worldwide rights to proteasome and immunoproteasome inhibitors from UC Riverside and MSU strengthen oncology assets and create licensing opportunities around targeted therapies.

Funding & Scale Modest revenue and early-stage funding indicate a need for strategic partnerships, sponsored research or platform access deals to scale efficiently without a large internal sales force.